Table 2 Correlation of HDL parameters to apoB for subsets of samples of normal male (M, n = 155) and female (F, n = 120), and of CETP mutants (CETP, n = 37). ApoB is treated in a logarithmic scale
From: ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
y | x | Regression | r2 | p |
|---|---|---|---|---|
HDL-C | apoB (M) | y = −20.7 ln(x) + 148.97 | 0.19402 | < 0.0001 |
|  | apoB(F) | y = −18.25 ln(x) + 145.65 | 0.12204 | < 0.0001 |
|  | apoB(CETP) | y = −18.11 ln(x) + 146.74 | 0.09913 | 0.0577 |
apoA-I | apoB (M) | y = 3.2611 ln(x) + 138.53 | 0.00095 | 0.7039 |
|  | apoB(F) | y = −12.28 ln(x) + 221.9 | 0.01573 | 0.1723 |
|  | apoB(CETP) | y = 7.8031 ln(x) + 132.09 | 0.00536 | 0.6668 |
apoA-II | apoB(M) | y = 6.9663 ln(x) + 4.9046 | 0.08481 | 0.0002 |
|  | apoB(F) | y = 6.9288 ln(x) + 4.6302 | 0.09889 | 0.0005 |
|  | apoB(CETP) | y = 5.0424 ln(x) + 14.743 | 0.07704 | 0.0963 |
apoA-I in LpAI | apoB(M) | y = −17.01 ln(x) + 127.03 | 0.10534 | < 0.0001 |
|  | apoB(F) | y = −21 ln(x) + 154.85 | 0.11063 | 0.0002 |
|  | apoB(CETP) | y = −15.75 ln(x) + 129.42 | 0.05717 | 0.1541 |
apoA-I in LpAI:AII | apoB(M) | y = 20.269 ln(x) + 11.498 | 0.06792 | 0.0011 |
|  | apoB(F) | y = 8.7152 ln(x) + 67.055 | 0.01481 | 0.1855 |
|  | apoB(CETP) | y = 23.554 ln(x) + 2.6636 | 0.14426 | 0.0204 |